ATE214942T1 - Fibrinogen-bildungsprotein - Google Patents

Fibrinogen-bildungsprotein

Info

Publication number
ATE214942T1
ATE214942T1 AT93921159T AT93921159T ATE214942T1 AT E214942 T1 ATE214942 T1 AT E214942T1 AT 93921159 T AT93921159 T AT 93921159T AT 93921159 T AT93921159 T AT 93921159T AT E214942 T1 ATE214942 T1 AT E214942T1
Authority
AT
Austria
Prior art keywords
formation protein
protein
fragment
fibrinogen formation
fibrinogen
Prior art date
Application number
AT93921159T
Other languages
English (en)
Inventor
Maria K Boden
Jan-Ingmar Flock
Original Assignee
Alfa Laval Agri Internat Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9202720A external-priority patent/SE9202720D0/xx
Priority claimed from SE9302955A external-priority patent/SE9302955D0/xx
Application filed by Alfa Laval Agri Internat Ab filed Critical Alfa Laval Agri Internat Ab
Application granted granted Critical
Publication of ATE214942T1 publication Critical patent/ATE214942T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT93921159T 1992-09-21 1993-09-20 Fibrinogen-bildungsprotein ATE214942T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9202720A SE9202720D0 (sv) 1992-09-21 1992-09-21 Fibrinogen binding protein
SE9302955A SE9302955D0 (sv) 1993-09-13 1993-09-13 A fibrinogen binding protein
PCT/SE1993/000759 WO1994006830A1 (en) 1992-09-21 1993-09-20 Fibrinogen binding protein

Publications (1)

Publication Number Publication Date
ATE214942T1 true ATE214942T1 (de) 2002-04-15

Family

ID=26661530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921159T ATE214942T1 (de) 1992-09-21 1993-09-20 Fibrinogen-bildungsprotein

Country Status (7)

Country Link
US (1) US6299879B1 (de)
EP (1) EP0621875B1 (de)
AT (1) ATE214942T1 (de)
AU (1) AU4837193A (de)
CA (1) CA2124210A1 (de)
DE (1) DE69331758T2 (de)
WO (1) WO1994006830A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
WO1995034655A2 (en) * 1994-06-07 1995-12-21 The Rockefeller University Surface protein of staphylococcus aureus
SE9402490D0 (sv) * 1994-07-15 1994-07-15 Jan Ingmar Flock Vitronection binding protein
US6013482A (en) * 1996-10-15 2000-01-11 Smithkline Beecham Plc Cell surface protein compounds
GB9521146D0 (en) * 1995-10-16 1995-12-20 Smithkline Beecham Plc Novel compounds
GB2306483B (en) * 1995-10-16 1998-09-23 Smithkline Beecham Plc Cell surface polypeptides of Staphylococcus aureus
US5858709A (en) * 1996-10-15 1999-01-12 Smithkline Beecham P.L.C. Fibronectin binding protein B compounds
WO1997014800A1 (en) * 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6107071A (en) * 1996-09-24 2000-08-22 Smithkline Beecham Corporation Histidinol dehydrogenase
US5882871A (en) * 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
EP1034277B1 (de) * 1997-11-26 2012-06-27 Inhibitex, Inc. Extrazelluläre Matrix-bindende Proteine von Staphylococcus aureus
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
WO2003041726A1 (en) * 2001-11-16 2003-05-22 Biostapro Ab Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug
US20030105020A1 (en) * 2001-11-16 2003-06-05 Jan-Ingmar Flock Use of a composition
EP1613642A4 (de) * 2003-04-16 2008-07-02 Texas A & M Univ Sys Efb-protein von staphylococcus aureus und c3-bindestelle, die die komplementaktivierung inhibiert
ES2360399T3 (es) 2003-07-08 2011-06-03 Umc Utrecht Holding B.V. Uso terapéutico de lpi, un inhibidor de la vía de las lectinas de origen estafilocócico, en enfermedades inflamatorias.
CA2684570A1 (en) 2007-04-19 2008-10-30 Molecular Detection Inc. Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria
JP5658564B2 (ja) * 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
CN101987866B (zh) * 2010-10-25 2013-01-23 中国人民解放军军事医学科学院基础医学研究所 金黄色葡萄球菌Efb蛋白C端抗原表位及其制备方法和用途
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
WO2015112895A2 (en) * 2014-01-24 2015-07-30 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
US11345744B2 (en) 2019-05-07 2022-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE454403B (sv) * 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability

Also Published As

Publication number Publication date
DE69331758D1 (de) 2002-05-02
DE69331758T2 (de) 2002-11-14
US6299879B1 (en) 2001-10-09
CA2124210A1 (en) 1994-03-31
WO1994006830A1 (en) 1994-03-31
EP0621875B1 (de) 2002-03-27
AU4837193A (en) 1994-04-12
EP0621875A1 (de) 1994-11-02

Similar Documents

Publication Publication Date Title
ATE214942T1 (de) Fibrinogen-bildungsprotein
DE69124371D1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
NO901399D0 (no) Aminosyrederivater.
DK1175909T3 (da) Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate
NO944997D0 (no) Trombin-blodfraksjon for anvendelse ved en medisinsk fremgangsmåte
EP0643559A4 (de) Rezeptorbindende region des diphtherietoxius.
DE69532760D1 (de) Mittel zur verabreichung von antigenen
AP9200410A0 (en) Retroviral protease inhibitors.
DK0601154T3 (da) BPC-peptider, deres fremstilling og anvendelse
ATE165976T1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
ATE304371T1 (de) Verwendung von staphylococcus enterotoxin homologe für krebs-therapie
DK162421C (da) Hundeparvovirus-vaccine, fremgangsmaade til fremstilling heraf og virusstamme til brug i vaccinen
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK675389D0 (da) Terapeutiske praeparater til forebyggelse af fibrinaflejringer
ES2092067T3 (es) Procedimiento de purificacion de una proteina altamente glicosilada.
DE3875859D1 (de) Zubereitungen zur verbesserung der adcc-therapien.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
DE69433745D1 (de) Modifizierte, verkürzte regulatoren des komplementsystems
DE69824862D1 (de) Zusammenstellungen zur verbesserten wundheilung
ES504996A0 (es) Un procedimiento para aislar un polipeptido purificado
ATE184287T1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
NO880034D0 (no) Fremgangsmaate for fremstilling av krystallinsk aminobeskyttet beta-benzyl-l-aspartinsyre.
BRPI9715268B8 (pt) preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties